Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage therapies for serious bacterial infections. Its lead programs include AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa. The company combines phage discovery, purification, and cGMP manufacturing capabilities at its Los Angeles-area McConnell Facility to support clinical development from early research through trial material production. Armata does not yet sell commercial products and remains dependent on clinical progress, regulatory milestones, and external funding.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational bacteriophage drug candidates being advanced through human trials for serious bacterial infections.
Government and consortium-funded cost reimbursement tied to specific development programs such as AP-SA02.
Customers
Armata’s direct customers are not commercial end-users but research sponsors, clinical investigators, and ultimately healthcare systems that would adopt its therapies if approved. In the current stage, revenue is primarily grant and award revenue tied to the AP-SA02 program, reflecting support from organizations such as MTEC rather than product sales. The company’s future commercial customers would likely include hospitals, infectious disease specialists, and pulmonary care providers treating difficult-to-manage bacterial infections. Because its therapies target drug-resistant or recurrent infections, the value proposition is clinical differentiation where standard antibiotics are inadequate or poorly tolerated.
Organizations such as MTEC that reimburse development costs for AP-SA02 and support clinical advancement before commercialization.
Hospitals and research centers in the United States and Australia that enroll patients and generate clinical evidence for the phage programs.
Infectious disease and pulmonary specialists who would use approved phage therapies for severe bacterial infections.
Patients with S. aureus bacteremia or chronic P. aeruginosa pulmonary disease who need alternatives to standard antibiotics.
Strategy
Armata’s strategy is to concentrate resources on a small number of phage programs with the clearest clinical and regulatory path, especially AP-SA02 for S. aureus bacteremia. The company is using its proprietary high-purity phage manufacturing capability as a differentiator, since repeat intravenous dosing requires consistent product quality and safety. It is also building the evidence base needed for an End-of-Phase-2 discussion with the FDA and a larger definitive efficacy trial. In parallel, Armata continues to rely on non-dilutive funding and may pursue complementary acquisitions or partnerships, but the near-term priority remains advancing current candidates toward approval.
AP-SA02 is the most advanced program and the clearest path to a registrational strategy in a high-unmet-need infection setting.
Repeat intravenous dosing and clinical scalability depend on reproducible purity and release processes.
The company has no product revenue and must fund ongoing R&D through grants, financing, or strategic arrangements.
A second validated program would diversify the pipeline and strengthen the platform thesis for phage therapeutics.
Geography
Armata is headquartered in Los Angeles, California, and its core research and manufacturing operations are concentrated there at the McConnell Facility. The company also ran AP-SA02 clinical sites in the United States and Australia, showing that its development footprint is international even though it remains U.S.-based. Its current business is therefore operationally centered in the United States, with trial execution extending to selected overseas sites when needed for enrollment and study design. Geography matters mainly through clinical trial access, regulatory pathways, and the ability to manufacture cGMP trial material close to development teams.
Risks
Armata faces the classic risks of a clinical-stage biotech company: clinical trial failure, regulatory setbacks, and the possibility that its phage platform does not translate into approvable products. The company explicitly notes that it may need additional capital and that failure to secure funding could force it to delay or eliminate programs, relinquish rights, or cease operations. Its dependence on a small number of programs increases concentration risk, while manufacturing complexity for highly purified phages could affect scalability, consistency, and regulatory acceptance. More broadly, the business is exposed to competition from antibiotics, alternative anti-infective approaches, and changing investor appetite for development-stage biotechnology.
The company has no commercial revenue and may need to raise funds to continue development, which could dilute shareholders or force program cuts.
Exposure: All development programs
AP-SA02 and AP-PA02 are still investigational, and negative efficacy or safety results would materially impair the platform thesis.
Even promising early data may not translate into FDA agreement on a registrational path or eventual approval.
Exposure: FDA pathway for phage therapies
Therapeutic phages require consistent purity and release standards, and any production issue could delay trials or commercialization.
Exposure: cGMP clinical material
Accounting
Judgemental itemsRevenue reflects sponsor reimbursement for AP-SA02 costs, so reported revenue depends on eligible spend and contract terms.
Impact: Can cause quarter-to-quarter variability unrelated to commercial demand
Changes in fair value produced significant gains and losses in recent periods, affecting net loss without changing cash flow.
Impact: Can materially distort earnings comparability
Clinical trial and manufacturing costs are estimated and accrued as services are received, which can shift expense recognition.
Impact: Affects operating loss timing
As a development-stage biotech, equity awards are an important part of compensation and non-cash expense.
Impact: Raises reported operating expenses and affects dilution analysis
The company must assess long-lived assets, intangible assets, and deferred tax assets for recoverability.
Impact: Could create non-cash charges if development prospects weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Aprea Therapeutics, Inc.
APRE · Pharmaceutical Preparations
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Carisma Therapeutics Inc.
CARM · Pharmaceutical Preparations
Last updated: 24/09/2026